Abstract:Abstract Colorectal Cancer (CRC) is the third most common cause of cancer mortality in the US. A major problem in CRC management is relapse and progression to metastatic disease leading to poor overall survival. The tumor suppressor p53 is mutated in most CRCs and often drives metastasis and therapy resistance. Current therapeutic options targeting p53 mutant cancers show poor efficacy and frequently exhibit high toxicity. To address this clinical problem, we developed a novel therapeutic strategy for selective targeting of p53 mutant cancers. The strategy combines a thymidine analogue (e.g., trifluorthymidine/TFT, a component of TAS102) and poly (ADP-ribose) polymerase inhibitor (PARPi). We observed that TAS102 does not block DNA replication, but rather prompts post-replicative base-excision DNA repair (BER), and PARPi increases double-strand DNA breaks (DSBs) in p53 mutant cancer cells. Normal p53 wild type (p53wt) cells are arrested in the G1 phase and repair DNA. Thus, the TAS102-PARPi combination selectively targets p53-mutant cancer cells, resulting in the accumulation of DSBs and cell death. This novel strategy was examined in p53wt and p53-mutant tumor cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models. The drug combination was significantly more effective in inhibiting p53 mutant tumor growth and in prolonging survival compared to monotherapies. This strategy is currently being tested in a first-in-human dose-escalation Phase I study (NCT04511039) in patients with advanced CRC. Further investigation revealed that the TAS102-PARPi combination induced DNA damage response (DDR) and the G2 checkpoint, leading to G2 arrest in p53 mutant cancer cells. We observed that TAS102-PARPi induced phosphorylation of CDC2 (also known as CDK1) but did not increase phosphorylation of histone H3 (a marker of mitosis), therefore indicating activation of the G2 checkpoint. Furthermore, the roles of ATM and ATR kinases in the DDR and G2 responses were clarified using highly specific kinase inhibitors. The analysis of the DDR/G2 signaling response in isogenic p53wt and mutant CRC cell lines showed that inhibition of WEE1 kinase can selectively abrogate the G2 checkpoint in p53-mutant cells, resulting in marked DNA damage and cell death. Importantly, the blockade of WEE1 strongly synergized with the TAS102-PARPi combination, further enhancing its potency and efficacy against p53-mutant cancer cells. In summary, our research provides a foundation for a novel therapeutic strategy for p53 mutant cancers that may provide a paradigm shift in the treatment of these deadly cancers, increasing efficacy while minimizing toxic adverse effects. Citation Format: Mohammed M. Alruwaili, Natsumi Naranjo, Priyanka Rajan, Kyeong Beom Jo, Dae-Kyum Kim, Thomas Melendy, Robert Straubinger, Christos Fountzilas, Andrei Bakin. Novel therapeutic approach for targeting p53 mutant colorectal cancers by affecting post-replicative DNA repair [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7590.

Abstract 3546: DNA-damaging Reagent -0404 Effectively Inhibits Hepatocellular Carcinoma Through P53-Dependent Autophagy

Abstract 1645: DNA-damaging Compound 0404 Effectively Inhibits Hepatocellular Carcinoma by Upregulation of Mir-34A and Mir-200C Expression

0404 Inhibits Hepatocellular Carcinoma Through a P53/mir-34A/sirt1 Positive Feedback Loop

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

Abstract 5289: Activating p53 through MDM2 and WIP1 inhibition effectively inhibits tumors in liver adenocarcinoma

Peptidylarginine Deiminase IV Promotes the Development of Chemoresistance Through Inducing Autophagy in Hepatocellular Carcinoma

Abstract 4867: Treating Hepatocellular Carcinoma Metastasis and Overcoming Chemoresistance Through Inhibiting the MDM2 Oncogene

Abstract C68: Suppression of AKT/mTOR Antiapoptotic Signaling by a Novel Drug Candidate Results in Growth Arrest and Apoptosis of Hepatocellular Carcinoma-Derived Cell Lines.

Enhancing Chemotherapy Sensitivity by Targeting PcG Via the ATM/p53 Pathway

Abstract 2070: HMGB1 Governs P53 to Autophagic Degradation Via Its Nucleus-to-cytoplasm Transport

Anti-GPC3 Antibody-Conjugated BEZ235 Loaded Polymeric Nanoparticles (Ab-Bez235-np) Enhances Radiosensitivity in Hepatocellular Carcinoma Cells by Inhibition of DNA Double-Strand Break Repair

Near-Infrared Light Irradiation Induced Mild Hyperthermia Enhances Glutathione Depletion and DNA Interstrand Cross-Link Formation for Efficient Chemotherapy

Andrographolide Causes p53-independent HCC Cell Death through p62 Accumulation and Impaired DNA Damage Repair

Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy.

Inhibition of Autophagy Promoted Apoptosis and Suppressed Growth of Hepatocellular Carcinoma Upon Photothermal Exposure.

Abstract 4280: the Cycloartane Triterpenoid ADCX Impairs Autophagic Degradation Through Akt Overactivation and Promotes Apoptotic Cell Death in Multidrug-Resistant HepG2/ADM Cells

Abstract 3081: Mir-885-5p, a P53-Activated Microrna, Inhibits the Wnt/β-catenin Signaling Pathway and Hepatocellular Carcinoma Metastasis.

Targeting Autophagy Potentiates Chemotherapy-Induced Apoptosis and Proliferation Inhibition in Hepatocarcinoma Cells.

The Apoptotic Effect and Associated Signalling of Hsp90 Inhibitor 17-Dmag in Hepatocellular Carcinoma Cells

Abstract 7590: Novel therapeutic approach for targeting p53 mutant colorectal cancers by affecting post-replicative DNA repair